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Background: The data are inconsistent regarding whether extreme N-terminal fragment pro-B-type natriuretic
peptide (NT pro-BNP) levels are associated with impaired renal function. Furthermore, the relationship between
extreme NT pro-BNP levels and cardiac and renal function in elderly patients has not been reported. The aim of the
present study was to examine a hypothesis that extreme NT pro-BNP levels may be associated with impaired
cardiac and renal function in elderly patients.
Methods: We retrospectively analyzed the data of demographic, clinical, and echocardiographic features on 152
consecutive elderly patients aged more than 80 years old (average age, 83.65 ± 3.58 years) with NT pro-BNP
levels≥ 3000 pg/ml. The participants were divided into two categories according to their NT pro-BNP levels: (1)
3000–10000 pg/mL and (2) >10000 pg /mL.
Results: The number of patients with impaired renal function (P = 0.019) and the mortality (P< 0.001) in the period
of inpatient was higher in the group with NT pro-BNP> 10000 pg /mL. The levels of serum creatinine and creatine
kinase MB (CK-MB) in the group of NT pro-BNP> 10000 pg / mL were higher than those in the group of NT pro-
BNP = 3000-10000 pg/mL (P = 0.001 and P = 0.023, respectively). Furthermore, no significant difference in the
distribution by NYHA class in different NT pro-BNP levels was observed. Multiple linear regression analyses
demonstrated that with NT pro-BNP levels as the dependent variable, NT pro-BNP levels were positively correlated
with CK-MB (β= 0.182, P = 0.024) and creatinine levels (β= 0.281, P = 0.001). The area under the receiver-operating
characteristic (ROC) curve of NT pro-BNP levels and clinical diagnosis of impaired renal function was 0.596 and
reached significant difference (95%CI:0.503-0.688, P = 0.044).
Conclusion: These data suggest that the extreme elevation of NT pro-BNP levels (≥3000 pg/ml) is mainly
determined by impaired renal function in elderly patients above 80 years. Extreme NT pro-BNP levels may be useful
for assessing the severity of impaired renal function.
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B-type natriuretic peptide (BNP; 77–108 amino acids) and
its N-terminal (1–76 amino acids) counterpart, NT-
proBNP, are cardiac biomarkers that have been established
for the assessment of left ventricular dysfunction and con-
gestive heart failure. Respecting NT pro-BNP has a longer
half-life than BNP, measurements of circulating levels of* Correspondence: fanli301301@yahoo.com.cn
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reproduction in any medium, provided the orNT pro-BNP have been prior recommended in the diag-
nosis and prognosis of patients with symptoms of left ven-
tricular dysfunction [1-3]. In addition, NT pro-BNP
testing is also important in the diagnostic and prognostic
evaluation of patients with Chronic kidney disease (CKD)
[4]. However, Law et al. [5] revealed that extreme values of
BNP were not associated with kidney dysfunction or the
presence of HF, cardiomyopathy. Interestingly, Guglin
et al. [6] demonstrated extremely high BNP levels (4000–
20,000 pg/mL) were correlated with renal dysfunction
measured by serum creatinine levels.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients, which is an independent risk factor for cardio-
vascular disease. The prevalence of CKD rises rapidly in
individuals older than 60 years of age [7]. It is well docu-
mented that adults lose about 1 mL/min/y of the glom-
erular filtration rate (GFR) from the age of 40 to
45 years. Given the increased incidence of impaired
renal function and NT pro-BNP levels in elderly patients
[8], we hypothesized that extreme NT pro-BNP levels
may be associated with impaired renal function in eld-
erly patients. Furthermore, the relationship between ex-
treme NT pro-BNP levels and cardiac and renal
function in elderly patients has not been reported. The
aim of the present study was to examine the hypothesis
that extreme NT pro-BNP levels may be associated with
impaired cardiac and renal function in elderly patients.
Methods
Ethical approval of the study protocol
This study complied with the Declaration of Helsinki. It
was approved by the Scientific and Ethics Review Board
of the Department of Geriatrics, Chinese PLA General
Hospital (Beijing, PR China). All patients provided writ-
ten informed consent to be included in the study.
Participants
We screened for elderly patients≥ 80 years, hospitalized
between April 2010 and January 2011, whose NT pro-
BNP values were ≥ 3000 pg/mL regardless of diagnosis.
According to the NT pro-BNP levels, the patients were
divided into two categories: 3000–10000 pg/mL
and> 10000 pg/mL. The cutoff of NT pro-BNP level
was chosen arbitrarily.
NT pro-BNP was determined by chemiluminescence
immunoassay, ADVIA Centaur™ system (Roche Inc.),
and was expressed as pg/ml. The normal value for the
NT pro-BNP test was <150 pg/mL. From the values
>3000 pg/mL measured during the same hospital ad-
mission, we calculated the average number. Laboratory
indicators, such as C-reactive protein (CRP), albumin,
creatine kinase MB (CK-MB) and creatinine levels,which
may be correlated with the NT pro-BNP level, were also
collected on the same day when NT pro-BNP exceeded
3000 pg/mL.
We reviewed medical records of all patients enrolled, in-
cluding history and physical examination findings, progress
notes and the data of instrumental and laboratory diagnos-
tic tests. From the clinical records available, we made the
diagnosis of heart failure (HF) and estimated functional
class by the New York Heart Association (NYHA).
Left ventricular ejection fraction (LVEF) was calculated
by means of echocardiographic study using Simpson’s
rule. Other parameters of structural and functional of
heart, such as left atrial diameter, right atrial diameter,interventricular septum, posterior wall, left ventricular
end systolic diameter (LVESD) and left ventricular end
diastolic diameter (LVEDD), fractional shortening (FS)
were also reviewed from electronic medical records
closed to the day when NT pro-BNP exceeded 3000 pg/
mL. Serum creatinine levels were recorded on the same
day that NT pro-BNP exceeded 3000 pg/mL. Impaired
renal function was defined as a serum creatinine
level> 1.5 mg/dL [9].
Statistical analysis
Results are presented as mean ± SD, as median and
interquartile ranges, or as percentages and numbers for
categorical data. Normality and homogeneity of var-
iances were tested for all variables. NT pro-BNP was
natural logarithmically transformed to normalize their
distributions. The Student’s t-test or Mann–Whitney U
two-sample tests (if the distribution was not normal)
were used to compare the continuous variables between
the two groups. Categorical data and proportions were
analyzed using the Mann–Whitney U or kruskal Wallis
H test where appropriate. Variables potentially asso-
ciated with the plasma concentration of NT pro-BNP in
all subjects were analyzed by linear regression analyses.
The relationship between NT pro-BNP and clinical diag-
nosis of HF or impaired renal function was tested with
the area under the receiver-operating characteristic
(ROC) curve. P< 0.05 was considered statistically sig-
nificant. All analyses were performed using SPSS for
Windows version 16.0 (SPSS, Chicago, IL, USA).
Results
Patient characteristics
Demographics are provided in Table 1. One hundred
and fifty-two consecutive patients (91 men and 61
women) with an age ranging from 80 to 94 (mean age,
83.65 ± 3.58 yr) were enrolled and underwent statistical
analysis. Among them, the NT pro-BNP levels of 108
patients (66 men) were between 3000 pg/mL and
10000 pg/mL (group A), 44 (25 men) ≥10000 pg/mL
(group B). Of the 152 participants, 16 patients admitted
with acute myocardial infarction, 69 with HF or HF ex-
acerbation, and 24 patients died during their
hospitalization. Among 83 patients without HF symp-
toms, the main reason of being hospitalized, including
infections (35 patients); brain damage such as stroke and
Parkinson’s disease (11 patients); cancer (25 patients);
and miscellaneous conditions (remaining 12 patients).
There were no significant differences between the
group A and the group B, when comparing age; having
atrial fibrillation, diabetes mellitus, hypertension, cancer,
chronic obstructive pulmonary disease or liver diseases;
echocardiographic parameters; and medications. More
patients with impaired renal function (P = 0.019) and
Table 1 Baseline characteristics of the enrolled patients with elevated NT pro-BNP levels
NT pro-BNP 3000-10000 pg/mL
(group A, n= 108)
NT pro-BNP ≥10000 pg/mL
(group B, n = 44)
P
Age (years) 83.57 ± 3.33 83.84 ± 4.18 0.679
Male, n (%) 66 (61.1) 25 (56.8) 0.625
BMI (kg/m2) 22.64 ± 3.79 21.50 ± 3.33 0.084
SBP(mm Hg) 126.69 ± 20.21 128.39 ± 23.19 0.653
DBP (mm Hg) 68.25 ± 12.37 66.32 ± 16.54 0.487
Underlying commodities disease, n (%)
Coronary artery disease 89(82.4) 37(84.1) 0.803
Atrial fibrillation 43(39.8) 15(84.1) 0.447
Diabetes mellitus 37(34.3) 19(43.2) 0.303
Hypertension 81(75.0) 36(81.8) 0.367
COPD 13(12.0) 4(99.1) 0.602
Respiratory failure 13(12.0) 7(15.9) 0.523
Cancer 29(26.9) 10(22.7) 0.860
Liver disease 10(9.3) 5(11.4) 0.694
MODS 6(5.6) 1(2.3) 0.383
Impaired renal function 39(36.1) 25(56.8) 0.019
Infection 57(52.8) 28(63.6) 0.223
Acute myocardial infarction 7(6.5) 4(9.1) 0.951
Death 9(8.3) 15(34.1) <0.001
Echocardiographic parameters
LVEF (%) 54.88 ± 10.44 53.41 ± 9.98 0.427
Left atrial diameter (mm) 39.39 ± 6.43 38.07 ± 5.34 0.231
Right atrial diameter (mm) 37.81 ± 6.85 36.39 ± 5.22 0.216
Interventricular septum (mm) 10.69 ± 1.57 10.80 ± 1.75 0.729
Posterior wall (mm) 10.06 ± 1.28 10.14 ± 1.75 0.753
LV diastolic dimension (mm) 49.98 ± 6.51 50.55 ± 5.42 0.613
LV systolic dimension (mm) 35.67 ± 6.41 35.93 ± 5.74 0.265
Fractional shortening (%) 29.81 ± 5.72 29.20 ± 4.79 0.297
Laboratory data
Creatinine (mg/dL) 1.24(0.92-1.82) 1.39(0.91-4.57) 0.001
CK-MB (ng/dL) 2.5(0.90-368) 3.63(1.72-5.77) 0.023
Serum albumin(g/dL) 33.44 ± 5.11 32.83 ± 6.76 0.540
C-reactive protein (mg/dL) 3.07(0.86-7.58) 3.44(1.025-8.6) 0.375
Medication, n (%)
ACEIs or ARBs 7 (6.5) 20 (45.5) 0.803
β-blockers 16(36.4) 48(44.4) 0.362
NT pro-BNP, N-terminal fragment pro-B-type natriuretic peptide;NS, not significant; BMI, body mass index; SBP, Systolic blood pressure; DBP, diastolic blood
pressure ;HF, heart failure; LV, left ventricular; MODS, multiple organ dysfunction syndrome; CK-MB, MB isoenzyme of creatine kinase; COPD, chronic obstructive
pulmonary disease. Data were shown as mean± SD, percentages and median values (quartile 1, quartile 3) for different parameters.
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hospitalization were found in the group B when com-
pared to group A. The levels of serum creatinine and the
CK-MB in the group B were higher than that in the
group A (P = 0.001, P = 0.023 respectively), but nodifference trend appeared in serum albumin and C-
reactive protein between the two groups.
No significant difference in the distribution by NYHA
class in different NT-pro BNP levels was observed be-
tween the group A and B presented in Table 2.




(group A, n= 108)
NT pro-BNP ≥10000
(pg/mL, %)
(group B, n = 44)
P
NYHAI 23 (21) 7 (16) NS
NYHAII 36 (34) 13 (30) NS
NYHAIII 31 (38) 15 (34) NS
NYHAIV 18 (17) 9 (20) NS
NYHA, New York Heart Association class; NT pro-BNP, N-terminal fragment pro-
B-type natriuretic peptide.
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Correlation analyses showed that NT pro-BNP levels
were positively correlated with CK-MB (r = 0.162,
P = 0.050) and creatinine (r = 0.237, P = 0.003). Multiple
linear regression analyses demonstrated that with NT-
pro BNP levels as the dependent variable, NT pro-BNP
levels were positively correlated with CK-MB (β= 0.182,
P = 0.024) and creatinine (β= 0.281, P = 0.001)(Table 3).
The area under the ROC curve of NT pro-BNP levels
and clinical diagnosis of HF was 0.582 and was not sig-
nificant (95%CI:0.474-0.690, p = 0.164) (Figure 1).Table 3 Correlation between clinical data,
echocardiographic parameters, laboratory data and NT
pro-BNP levels
Univariate Multivariate
r P β P
Age −0.017 0.832 - NS
BMI −0.134 0.099 −0.151 0.058
Systolic blood pressure −0.029 0.726 - NS
Diastolic blood pressure −0.122 0.134 - NS
Echocardiographic parameters
LVEF −0.085 0.300 - NS
Left atrial diameter −0.031 0.701 - NS
Right atrial diameter −0.093 0.254 - NS
Interventricular septum −0.078 0.341 - NS
Posterior wall −0.022 0.787 - NS
LV diastolic dimension 0.054 0.512 - NS
LV systolic dimension 0.028 0.730 - NS
Fractional shortening 0.012 0.883 NS
Laboratory data
Creatinine 0.237 0.003 0.281 0.001
CK-MB 0.162 0.050 0.182 0.024
Serum albumin, −0.078 0.337 - NS
C-reactive protein 0.131 0.341 - NS
NT pro-BNP, N-terminal fragment pro-B-type natriuretic peptide; NS, not
significant; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HF, heart failure; LV, left ventricular; CK-MB, MB isoenzyme of
creatine kinase.However, the area under the ROC curve of NT pro-BNP
levels and clinical diagnosis of impaired renal function
was 0.596 and reached significant difference (95%
CI:0.503-0.688, p = 0.044) (Figure 1).
Discussion
In the present study, we found extreme NT pro-BNP
levels were positively correlated with creatinine levels
and the evaluation of impaired renal function in elderly
patients. Elevated NT pro-BNP levels are common in
patients with CKD, as it showed in the presence of cor-
onary artery disease (CAD) and left ventricular hyper-
trophy (LVH). Nitta and colleagues [10] reported that
the mean serum NT pro-BNP concentration was higher
in haemodialysis patients than in normal healthy sub-
jects. Yang et al. [11] demonstrated that BNP levels of
patients with CKD showed a positive correlation with
creatinine levels, and a high concentration of BNP can
be seen in patients with stage 5 CKD without heart fail-
ure. After analyzing 277 patients with CKD, Prnjavorac
et al. [12] found that NT pro-BNP increased at the be-
ginning of water overload in patients with CKD. How-
ever, Law et al. [5] demonstrated that BNP levels were
not correlated with the presence of renal dysfunction in
113 patients with BNP value >3000 pg/mL. The major
reason for this inconsistency maybe that patients with
an age ranging from 21 to 102 were enrolled in Law’s
study , which may lead to different result regarding BNP
levels determined by age. Moreover, our results are simi-
lar to the study by Guglin et al. [6], who also found high
BNP levels (4000–20,000 pg/mL) were associated with
kidney dysfunction. Although the data are inconsistent,
our results suggest in elderly patients, the extreme NT
pro-BNP may be more useful for the assessment of the
severity of impaired renal function. Certainly, further
studies are still needed to ascertain the relationship be-
tween extreme BNP levels and impaired renal function
in large sample size.
Previous evidence demonstrated that BNP testing is a
useful tool for the diagnosis or stratification of decompen-
sated heart failure [13,14]. Most studies have confirmed
that BNP is associated with the severity of HF in a certain
range. However, a study regardless of age published in
2010 demonstrated that extreme values of BNP do not
correlate with the presence of HF [15]. Our results also
showed that there was no significant difference in the dis-
tribution by NYHA class and LVEF in different NT pro-
BNP levels. There are several possible reasons for this
phenomenon. Firstly, immunoassays play an important
role in falsely elevating BNP levels, which are used in the
clinical setting and do not determine precise molecular
forms of these natriuretic peptides. A review showed anti-
bodies against BNP may also recognize and bind to pro-
BNP and NT-fragments [16]. Meanwhile, analysis from
Figure 1 The ROC curve of NT pro-BNP levels and clinical diagnosis of HF (Figure A) and impaired renal function (Figure B). AUC= area
under the curve; CI = confidence interval; ROC= receiver-operating characteristic.
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BNP forms often predominate in HF,. This indicates that
the bioactive forms of natriuretic peptides may not be pro-
cessed proportionally in patients with advanced HF. Sec-
ondly, inflammation may be associated with falsely
elevating BNP levels. Because one study had demonstrated
that inflammatory markers were positively correlated with
BNP levels, suggesting a link between elevations of BNP
levels and inflammation [17].
Through a systematic review of 19 studies, Doust and
colleagues found that NT pro-BNP is a strong prognos-
tic indicator for both asymptomatic patients and for
patients with heart failure at all stages of disease, and for
every 100 ng/L rise in NT pro-BNP concentration, there
was a corresponding 35% increase in the relative risk of
death [18]. Additionally, a previous cohort study showed
that NT pro-BNP was found to be a good predictor of
mortality in elderly with and without specific cardiac
diagnoses [19]. Bettencourt and colleagues [20] also
demonstrated that NT pro-BNP levels were the stron-
gest independent predictor of death or hospital readmis-
sion during hospitalization and six months of follow-up.
In the extremely elevated geriatric population above
80 years, we found higher levels of NT pro-BNP with
higher mortality. These results confirmed that even with
the level above 3000 pg/ml and suggested that NT pro-
BNP may be also an independent predictor of death in
elderly patients with or without cardiac disease.
In the early phase of AMI, NT pro-BNP gene expres-
sion increases considerably, the phenomenon also can
be seen in human cardiac allograft acute rejection [21].
Therefore, NT pro-BNP is a useful marker of reflection
injury of myocardium function and prognostic of myo-
cardial infarction [22]. Moreover, NT pro-BNP level issimilar to BNP in circulation of healthy volunteers and it
proportionally increse as cardiac function deterioration
[23,24]. After compared the predictive value of NT pro-
BNP and other frequently used biomarkers, Melki et al.
recently found that NT pro-BNP may be the best single
predictor of left ventricular function in patients with
non-ST-segment elevation acute coronary syndromes
[25]. In the present study, although there was no differ-
ence in the ratio of acute myocardial infarction patients
in admission in different level of NT pro-BNP, we found
the weak correlation between NT pro-BNP and CK-MB,
and higher levels of CK-MB accompanied with higher
NT pro-BNP, suggests elevated CK-MB levels derived
from AMI contribute to the elevation of NT pro-BNP.
In recent years, CRP has emerged as a possible potent
risk marker for cardiovascular diseases [26,27]. The cor-
relation between CRP and BNP levels has also been
demonstrated [17], which means a possible interaction
between natriuretic peptides and the systemic inflamma-
tory response. Conversely, Caroline and collegues [28]
found that CRP levels are not independently associated
with first cardiovascular events in older individuals, and
increasing age seems to attenuate the association be-
tween plasma CRP levels and the risk of cardiovascular
disease. We also observed the levels of CRP in the study,
but didn’t find the correlation between NT pro-BNP and
CRP.
In addition, multiple factors are known to influence
the circulating levels of NT pro-BNP. The prevalence of
possible influencing factors including gender, body mass
index (BMI), anemia and medications for heart failure
such as ACE inhibitors, angiotensin-receptor blockers,
beta blockers [29-31], but in the present study, we didn’t
find the correlation between BNP and all of them.
Cui et al. BMC Cardiovascular Disorders 2012, 12:57 Page 6 of 7
http://www.biomedcentral.com/1471-2261/12/57Maybe these parameters are just confounding variables,
and the underlying mechanism still needs to be further
revealed.
There are several limitations in the present study.
Firstly, the cutoff of NT pro-BNP for the enrolment and
groups was established arbitrarily. Secondly, we only en-
rolled elderly patients above 80 years, and the popula-
tion with the characteristics of more comorbidities and
more severe conditions, that bring about a more con-
founding factor.
Conclusions
In conclusion, our results suggest that in elderly patients
above 80 years, extreme elevation of NT pro-BNP
(≥3000 pg/ml) is mainly determined by impaired renal
function. Extreme NT pro-BNP levels may be useful for
the assessment of the severity of impaired renal
function.
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